Date(s) – 17/03/2021 – 30/04/2021
New treatment modalities such as targeted therapies and immune therapies pose new and unique challenges. To help address the most profound of these challenges, the LCRF-AstraZeneca grant program aims to fund innovative projects to:
Understand primary and acquired resistance to osimertinib and novel combinations targeting concurrent driver mutations
Develop more effective approaches to address disease progression in patients treated with durvalumab
Discover novel biomarkers for predicting response to osimertinib or durvalumab and to identify patients who are at higher risk of recurrence (translational research preferred)
Identify predictive biomarkers, understand the underlying biology and develop novel interventions for immune mediated adverse events, such as pneumonitis, in patients receiving durvalumab
These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators. Proposals which specifically focus on either osimertinib or durvalumab will be strongly favored. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. Letters of Intent will be accepted through April 30, 2021.